Amgen Posts 77% Response In Thyroid Eye Disease Study

All NewsApril 6, 2026

Amgen shares fall despite Phase 3 TEPEZZA OBI data showing 77% response rate and proptosis reduction in thyroid eye disease patients.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent